Glucose IV Solutions Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 2.40 Billion |
| Market Size (2029) | USD 3.5 Billion |
| CAGR (2024 - 2029) | 7.50 % |
| Fastest Growing Market | Asia |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players.webp){kind=logo}
*Disclaimer: Major Players sorted in no particular order |
Glucose IV Solutions Market Analysis
The Glucose IV Solutions Market size is estimated at USD 2.40 billion in 2024, and is expected to reach USD 3.5 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).
The glucose IV solutions market is witnessing robust growth, propelled by a surge in gastrointestinal diseases and an aging population, as it plays a crucial role in medical treatments.
Also, the market's momentum is fueled by the escalating prevalence of gastrointestinal ailments. Notably, conditions like ulcerative colitis, irritable bowel syndrome, Crohn's disease, celiac disease, and gastroenteritis are on the rise. A report published by Elsevier Ltd in August 2023 highlighted a global prevalence of 5 million cases of ulcerative colitis, with incidence rates on a noticeable uptrend. Given this high disease burden, the demand for glucose IV fluids as effective medical solutions is rising.
Glucose IV fluids play a crucial role in rehydrating the body, offering essential glucose for recovery. These solutions combat dehydration and serve as a vital energy source, especially for patients undergoing gastrointestinal treatments. Their ability to efficiently hydrate and energize patients underscores their indispensable nature in medical settings.
Similarly, developing economies are increasingly turning to glucose IV solutions. With improving healthcare infrastructure and a growing awareness of intravenous treatments, these regions are embracing glucose IV solutions, especially in areas with high gastrointestinal disease burdens and expanding elderly populations.
Thus, the glucose IV solutions market is set for sustained growth, driven by the surge in gastrointestinal diseases, the aging demographic, and the escalating demand from developing regions. The efficacy of dextrose-based IV solutions in treating dehydration, providing nutritional support, and managing low blood sugar and insulin shock further cements the significance in modern healthcare.
Glucose IV Solutions Market Trends
The Glucose 10% IV Segment is Expected to Hold a Significant Market Share During the Forecast Period
The glucose 10% IV segment is projected to grow substantially during the forecast period.
Glucose 10% w/v solution for infusion is essential in various medical applications, including providing carbohydrates during parenteral nutrition, preventing and treating hypoglycemia, rehydrating patients experiencing water loss and dehydration, and diluting compatible medicinal products. As a sterile hypertonic solution of glucose in water for injections, glucose 10% is crucial in scenarios where the gastrointestinal tract cannot be used, such as extensive burns, or where protein absorption is impaired, and metabolic requirements for protein are significantly increased.
The demand for glucose 10% IV solutions is closely linked to the rising incidence of gastrointestinal-related diseases. For instance, according to a June 2023 fact sheet by the Crohn's & Colitis Foundation, between 1.6 and 3.1 million Americans are affected by inflammatory bowel disease (IBD), with approximately 70,000 new diagnoses made each year. These conditions lead to gastrointestinal tract inflammation, resulting in symptoms like persistent diarrhea, abdominal discomfort, and hematochezia. In such cases, glucose IV solutions play a critical role in managing symptoms and providing necessary nutritional support.
Also, the rising adoption of intravenous (IV) therapy for drug administration, particularly among the elderly and neonatal demographics, is a key driver propelling the market for glucose 10% solutions. A study conducted by Nationwide Children's Hospital, released in April 2024 on Medscape, highlights that the standard approach for treating pediatric hypoglycemia involves administering an intravenous bolus of dextrose 10% at a rate of 2.5 ml per kilogram. Additionally, premature infants and those small for their gestational age are often administered glucose IV shortly after birth to prevent hypoglycemia, highlighting the essential role of glucose IV solutions in neonatal care.
The MedSafe dataset from New Zealand, published in May 2022, underscores the importance of glucose 10% solutions in medical practice. The dataset describes glucose 10% as a sterile hypertonic solution without preservatives, ideal for preventing nitrogen loss and treating negative nitrogen balance in patients unable to use the alimentary tract. This includes patients with extensive burns or impaired gastrointestinal protein absorption, indicating a high metabolic requirement for protein.
As gastrointestinal-related diseases become more prevalent and the need for effective intravenous therapies grows, glucose 10% IV solutions are expected to rise. This trend is bolstered by the increasing demand for efficient nutritional support and rehydration therapies across various patient demographics, including those with heightened carbohydrate needs.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America stands out as a considerable market for glucose IV infusion solutions, driven by a high incidence of diabetes and chronic diseases and a well-established healthcare infrastructure.
The increasing prevalence of diabetes in North America underscores the critical need for effective glucose management solutions. The American Diabetes Association defines hypoglycemia, a common complication among diabetic patients, as any episode where plasma glucose concentration drops to 70 mg/dL (3.9 mmol/L) or lower, potentially causing harm. This condition necessitates prompt and efficient treatment, often involving glucose IV infusions to quickly restore normal blood sugar levels.
Moreover, the region faces a substantial burden of gastrointestinal illnesses, such as norovirus or stomach flu. National Foundation for Infectious Diseases article from July 2023 reported that in the United States, norovirus caused between 19 and 21 million cases of diarrhea and vomiting in 2023. This surge resulted in 465,000 emergency room visits and 109,000 hospitalizations. Notably, the winter of 2023 witnessed a pronounced spike in norovirus incidents, with the peak occurring in March and the trend extending into late spring. Patients typically refrain from solid foods during such outbreaks, underscoring the importance of glucose IV therapy to sustain energy and hydration.
The application of glucose IV solutions extends beyond immediate medical emergencies. In November 2023, University Hospitals Seidman Cancer Center announced a clinical trial to explore the potential benefits of high glucose levels in enhancing the efficacy of chemotherapy for pancreatic cancer patients. This innovative approach involves artificially raising patients' blood sugar with intravenous glucose infusions concurrent with chemotherapy, aiming to improve treatment outcomes. Such advancements highlight the expanding role of glucose IV solutions in diverse medical applications, from managing diabetes and gastrointestinal disorders to supporting cancer treatment.
The robust healthcare system in North America further supports the growth of the glucose IV solutions market. Well-established hospitals and medical facilities ensure patients can access advanced treatment options, including intravenous therapies. Additionally, continuous research and development efforts contribute to the optimization of glucose IV formulations and delivery methods, enhancing their effectiveness and safety.
Glucose IV Solutions Industry Overview
The glucose IV solutions market is semi-consolidated and consists of various players. Many regional and global players employ vertical collaboration as a critical strategy to grow their market presence. Major players include Baxter, B. Braun Medical Inc., Fresenius Kabi AG, ICU Medical Inc., and Becton, Dickinson and Company.
Glucose IV Solutions Market Leaders
-
Baxter
-
B. Braun Medical Inc.
-
Fresenius Kabi AG
-
ICU Medical, Inc.
-
Becton, Dickinson and Company
*Disclaimer: Major Players sorted in no particular order
Glucose IV Solutions Market News
- March 2024: Otsuka Pakistan Limited initiated the renovation and upgrade of its glucose IV solutions manufacturing facilities, focusing on products such as glucose IV to enhance product quality.
- March 2024: Baxter published the US Hospital Products Availability Report, highlighting the availability of key products, including glucose 5% IV solution.
Glucose IV Solutions Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Prevalence of Gastrointestinal and Chronic-related Diseases
4.2.2 Rise in the Geriatric Population
4.3 Market Restraints
4.3.1 Stringent Regulatory Scenario
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Dose Type
5.1.1 Glucose 5%
5.1.2 Glucose 10%
5.1.3 Glucose 20%
5.1.4 Glucose 50%
5.1.5 Glucose 70%
5.1.6 Other Dose Types
5.2 By Size
5.2.1 100 ml
5.2.2 500 ml
5.2.3 1,000 ml
5.2.4 Other Sizes
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter
6.1.2 B. Braun Medical Inc.
6.1.3 Fresenius Kabi AG
6.1.4 ICU Medical Inc.
6.1.5 Becton, Dickinson and Company
6.1.6 CDM LAVOISIER
6.1.7 Wallcur LLC
6.1.8 Nasco Healthcare
6.1.9 Otsuka Pharmaceutical Factory Inc.
6.1.10 JW Holdings
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Glucose IV Solutions Industry Segmentation
An intravenous glucose solution, commonly called a dextrose solution, combines glucose (dextrose) with water. This solution is primarily employed to address low blood sugar levels or dehydration without an accompanying loss of electrolytes. Dehydration without electrolyte imbalance can manifest in conditions such as fever, hyperthyroidism, elevated blood calcium levels, or diabetes insipidus.
The glucose IV solutions market is segmented into dose type, size, and geography. By dose type, the market is segmented into glucose 5%, glucose 10%, glucose 20%, glucose 50%, glucose 70%, and other dose types. By size, the market is segmented into 100 ml, 500 ml, 1,000 ml, and other sizes. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market sizing and forecasts are based on revenue (USD).
| By Dose Type | |
| Glucose 5% | |
| Glucose 10% | |
| Glucose 20% | |
| Glucose 50% | |
| Glucose 70% | |
| Other Dose Types |
| By Size | |
| 100 ml | |
| 500 ml | |
| 1,000 ml | |
| Other Sizes |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Glucose IV Solutions Market Research FAQs
How big is the Glucose IV Solutions Market?
The Glucose IV Solutions Market size is expected to reach USD 2.40 billion in 2024 and grow at a CAGR of 7.5% to reach USD 3.5 billion by 2029.
What is the current Glucose IV Solutions Market size?
In 2024, the Glucose IV Solutions Market size is expected to reach USD 2.40 billion.
Who are the key players in Glucose IV Solutions Market?
Baxter, B. Braun Medical Inc., Fresenius Kabi AG, ICU Medical, Inc. and Becton, Dickinson and Company are the major companies operating in the Glucose IV Solutions Market.
Which is the fastest growing region in Glucose IV Solutions Market?
Asia is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Glucose IV Solutions Market?
In 2024, the North America accounts for the largest market share in Glucose IV Solutions Market.
What years does this Glucose IV Solutions Market cover, and what was the market size in 2023?
In 2023, the Glucose IV Solutions Market size was estimated at USD 2.22 billion. The report covers the Glucose IV Solutions Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Glucose IV Solutions Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Glucose IV Solutions Industry Report
Statistics for the 2024 Glucose IV Solutions market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Glucose IV Solutions analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
